kabutan

Tsubota Laboratory Incorporated(4890) Summary

4890
TSE Growth
Tsubota Laboratory Incorporated
292
JPY
-5
(-1.68%)
Apr 30, 11:27 am JST
1.82
USD
Apr 29, 10:27 pm EDT
Result
PTS
outside of trading hours
293.5
Apr 30, 11:09 am JST
Summary Chart Historical News Financial Result
PER
PBR
6.82
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
295 JPY 1.84 USD
Previous Close Apr 28
297 JPY 1.86 USD
High Apr 30, 9:00 am
295 JPY 1.84 USD
Low Apr 30, 9:05 am
290 JPY 1.81 USD
Volume
36,500
Trading Value
0.01B JPY 0.07M USD
VWAP
292.57 JPY 1.82 USD
Minimum Trading Value
29,200 JPY 182 USD
Market Cap
7.53B JPY 0.05B USD
Number of Trades
67
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Mid
1-Year Average
339
1-Year High Mar 13, 2026
17,552
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 979,000
Apr 17, 2026 0 977,900
Apr 10, 2026 0 1,014,100
Apr 3, 2026 0 1,103,400
Mar 27, 2026 0 1,178,900
Company Profile
Tsubota Laboratory Incorporated is a biotech venture originating from Keio University. The company focuses on research and development of pharmaceuticals for myopia, dry eye, presbyopia, and brain activation.
Sector
Pharmaceuticals
Tsubota Laboratory Incorporated, a biotech venture born out of Keio University School of Medicine, aims to create groundbreaking innovations in the treatment of myopia, dry eye, presbyopia, and brain-related disorders. The company conducts advanced research in collaboration with affiliated universities and pursues joint development with partner companies to evaluate research outcomes. Its business model is based on generating revenue through joint research and development agreements, licensing agreements, upfront payments, milestone payments, and post-commercialization royalties, which are then reinvested into new research in a cyclical manner. A distinctive feature of the company is its research and development utilizing the high-level expertise of external contracted researchers. Tsubota Laboratory Incorporated adopts a dual strategy, simultaneously developing and marketing pharmaceuticals and medical devices alongside commodity products.